Academic scientists who identify as change makers, researching and addressing healthcare problems with potential for long-term social impact
“The Termeer Foundation is committed to championing emerging biotechnology leaders and finding people who want to solve the biggest problems in human health. By supporting researchers, we plant the seeds for future success in individuals who are preparing to make significant contributions in academia and industry.”
BELINDA TERMEER, President of The Termeer Foundation
Support & pilot grants
for academics solving healthcare challenges
The Termeer Scholar Award supports and elevates leaders and scholars who are making an impact on the world by developing scientific advances like new medicines and diagnostics that represent the future of the biotechnology industry and the potential to positively impact patients’ lives. The Award is intended to support individuals who have and ignite excitement for solving the biggest problems in human health and treatment delivery. The focus of the research of a Termeer Scholar is on advancing treatments and cures for patients.
MEET OUR 2023 SCHOLAR
Winston Yan
President, N=1 Collaborative (N1C)
PAST SCHOLARS
Keep up with the work of the Termeer Scholar Award receipients by following the links below to their LinkedIn profiles.
2022 SCHOLAR AWARD HONOREES
(2022 ROLE)
Omar Abudayyeh (McGovern Fellow at Massachusetts Institute of Technology)
Jonathan Gootenberg (McGovern Fellow at Massachusetts Institute of Technology)
Winston Yan
President, N=1 Collaborative (N1C)
Winston Yan is a founding member and President of the N=1 Collaborative (N1C), and Co-founder and Head of Translational Strategy at Arbor Biotechnologies. He is motivated to bring the promise of genetic medicines to help the broadest range of patients — particularly those with ultra-rare, “N-of-few” genetic diseases that otherwise would be too rare to attract commercial interest. The emergence of genetically programmable treatments such as CRISPR, ASOs, and siRNAs over the past decade are hugely enabling, but unlocking their full rare disease potential requires data sharing, standardization, and close collaboration between academia and industry. The N=1 Collaborative is a nonprofit that serves as an independent, neutral hub to enable sharing best practices, communal resources, and preclinical/clinical data, all to accelerate the creation of a safe, rigorous, and scalable N-of-1 drug development process. Prior to N1C and Arbor, Winston completed his undergraduate degree in Physics magna cum laude at Harvard College, M.D. from Harvard Medical School (Health Sciences & Technology track), and Ph.D. from Harvard University working with Feng Zhang at the Broad Institute on early CRISPR genome editing technology development. Winston is dedicated to bringing together the scientific, strategic, and entrepreneurial threads of his background to collaboratively realize this vision for the millions of patients worldwide with genetic disease.